3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial

Sponsor: M.D. Anderson Cancer Center

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT05674396

Patient View

This Phase II trial evaluates the efficacy of SBRT versus traditional radiation for palliation in head and neck squamous cell carcinoma patients ineligible for curative treatment. It compares outcomes like local progression-free survival, pain response, and toxicity. Eligible participants are adults with confirmed carcinoma, excluding those with radiotherapy contraindications or pregnant women.

Patient Parameters

Program Overview

To learn if it is effective to use advanced radiation treatment techniques (stereotactic radiation or "SBRT") to safely deliver a strong dose of radiation to your tumor in a shorter period of time than would typically be feasible with traditional methods.

Description

Objectives:

  • To compare local progression-free survival following palliation with SBRT versus traditional fractionations in patients with HN SCC deemed ineligible for curative-intent treatment.
  • To compare pain response, symptom burden, toxicity, local control, progression-free survival, and overall survival between the treatment modalities.

Eligibility Criteria

Inclusion Criteria

  • Age 18 or older
  • Willing to provide informed consent
  • Histologically confirmed squamous cell carcinoma
  • Primary tumor site in the head and neck (includes oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, salivary gland, and cutaneous subsites as well as tumors of unknown primary site)
  • Ineligible for curative intent treatment after multidisciplinary evaluation (including evaluation by radiation oncologist and surgeon followed by presentation at multidisciplinary tumor board prior to randomization)
  • Prior therapy including radiation, surgery, or systemic therapy is permitted unless further radiation is deemed inappropriate by the enrolling physician
  • Metastatic disease is permitted

Exclusion Criteria

  • Contraindications to radiotherapy
  • Pregnant or lactating women

5.0 PRE-TREATMENT EVALUATION

  • History and physical examination including laryngopharyngoscopy by a radiation oncologist and/or head and neck surgeon within 8 weeks prior to randomization.

    o Clinical examination will include a detailed description of disease target including measurement where feasible to facilitate response assessment

  • Documentation of smoking history

  • Staging imaging within 12 weeks prior to randomization:

    • Contrast-enhanced CT of the neck and chest or
    • MRI of the neck with CT of the chest or
    • Whole body PET/CT

  • Histological confirmation of squamous cell carcinoma

  • Pregnancy test for women of child-bearing age, within 2 weeks prior to randomization

  • Assessment of all baseline symptoms, using CTCAE version 5.0 within 2 weeks prior to randomization.

  • Assessment of baseline pain score (NRS) and analgesic use (non-opioid and opioid)

  • Completion of QOL scoring within 2 weeks of randomization

  • Informed consents must be obtained prior to any study specific activities

Get This Program In Your Inbox

You can sign up and apply your patients for this program.